UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 10, 2022

EXAGEN INC.
(Exact name of registrant as specified in its charter)

Delaware	001-39049	20-0434866
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1261 Liberty Way
Vista, CA 92081
(Address of principal executive offices) (Zip Code)

(760) 560-1501
(Registrant's telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	**XGN**	**The Nasdaq Global Market**

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Exagen Inc. is furnishing with this Current Report on Form 8-K a copy of its current presentation slides regarding its AVISE® RADR testing solution. The information in these slides shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	AVISE RADR Presentation Slides, dated January 10, 2022
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EXAGEN INC.

Date: January 10, 2022

By: /s/ Kamal Adawi
Kamal Adawi
Chief Financial Officer

Exagen®

Patient Focused. Discovery Driven.

AVISE® RADR

Rheumatoid **A**rthritis **D**rug **R**esponse

Disclaimer

This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, , current and future product offerings, including AVISE RADR, reimbursement and coverage, our ability to implement an integrated testing with therapeutics strategy, the expected benefits from our partnership or promotion arrangements with third parties, research and development costs, timing and likelihood of success and plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These known risks and uncertainties are described in detail in our filings with the SEC from time to time, including under the heading "Risk Factors" in our Annual Report on Form 10-K and any subsequent filings with the SEC.

In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

We obtained the industry, market and competitive position data used throughout this presentation from our own internal estimates and research, as well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In addition, while we believe our own internal research is reliable, such research has not been verified by any independent source and you are cautioned not to give undue weight to such estimates.

Precision Medicine for Rheumatoid Arthritis

AVISE® RADR

Own the Hilltop

Exagen has a well-respected and proven rheumatology infrastructure

Sizable TAM

Rheumatoid arthritis affects 2M patients and adds 120K new patients per year[1]

Minimally Invasive

Synovial tissue is collected from a biopsy that takes place inside an existing rheumatologist's office

Unmet Need

Currently, 70%–80% of RA patients fail to reach low disease activity[2]

Exclusive Rights

Exagen holds the exclusive worldwide license to the IP rights

Innovative Platform

First rule-in therapy selection test for rheumatoid arthritis

Payor Benefits

Reduces patient cycling - Potentially large savings for payors

References:
1. Myasoedova et al. Arthritis & Rheumatology 2010
2. Pitzalis et al. Nature Reviews Rheumatology. 2020.


Significant Unmet Needs
4
EXAGEN CONFIDENTIAL
Exagen

Low Patient Response Rates



Do NOT achieve an ACR20 response

Do NOT achieve an ACR50 response

Do NOT achieve an ACR70 response

***ACR response rates include all RA therapeutics**

References:
Pitzalis et al. Nature Reviews Rheumatology. 2020.

Large Addressable Market

120,000

Americans diagnosed with RA every year[1]

~2 Million

Existing patients in the U.S. living with RA[1]

$30B

Total RA Therapeutic U.S. Market each year[2]

70%-80%

RA patients fail to reach low disease activity[3]

$18B in Wasted RA Therapeutic Spend

References:
1. Myasoedova et al. Arthritis & Rheumatology 2010
2. IQVIA DDD Data; IBM Truven patient claims data; Cowen Therapeutic Categories Outlook Feb 2021
3. Pitzalis et al. Nature Reviews Rheumatology. 2020.


Precision Medicine Approac
Helps Guide Treatment
7
EXAGEN CONFIDENTIAL
Exagen

A Formula for RA Precision Medicine

An 'Individual Patient Signature' is based on the following features:



Clinical disease activity indices

Gene expression analysis performed on synovial tissue

Proteomics RA lab test

AVISE® RADR

References:
Ribera et al. Annals of Rheumatic Diseases. 2019.

The AVISE RADR Approach to Personalized Medicine

1. **Synovial Biopsy**
   Patients undergo a minimally invasive procedure to collect 6 biopsies in one visit
2. **Gene Expression Profiling**
   Performed on synovial tissue collected from an affected joint; pathotype is determined
3. **Personalized Medicine**
   The patient's pathotype is matched to the therapy most likely to lead to response



Rheumatoid Arthritis Pathotypes

RA pathotypes are defined by the type of immune cells present in affected joints



References:
Lewis et al, Cell Reports. 2019; Kelly et al. Ann Rheum Dis. 2015

Synovial Biopsy is Superior to Other Methods

8

differently expressed transcripts
in blood

3,000

differently expressed transcripts
in synovial tissue

References:
Lewis et al, Cell Reports. 2019; Kelly et al. Ann Rheum Dis. 2015

The Value of Precision Medicine

Existing Patient Journey[1]



Once a patient fails to respond, a doctor has 12 drugs to choose from, with no current rule-in test to guide their decision.

AVISE RADR Patient Journey

Speed and accuracy in the treatment selection has the potential to protect a patient's joints and be cost effective.

References:
1. Lewis et al. Cell Reports. 2019

AVISE RADR Position in the Patient Journey




Owning the Hilltop
AVISE RADR expands our well-respected and proven portfolio
14 EXAGEN CONFIDENTIAL
Exagen

Exagen is a Leader in Rheumatology

Exagen has a highly respected rheumatology salesforce in place with support and infrastructure ready to go



What does this mean for Rheumatologists?

- Minimally invasive
- Uses existing equipment
- Replaces the issues with rule-out empirical treatments with precision personalized medicine

Precision Medicine for Rheumatoid Arthritis

AVISE® RADR

Own the Hilltop

Exagen has a well-respected and proven rheumatology infrastructure

Sizable TAM

Rheumatoid arthritis affects 2M patients and adds 120K new patients per year[1]

Minimally Invasive

Synovial tissue is collected from a biopsy that takes place inside an existing rheumatologist's office

Unmet Need

Currently, 70%–80% of RA patients fail to reach low disease activity[2]

Exclusive Rights

Exagen holds the exclusive worldwide license to the IP rights

Innovative Platform

First rule-in therapy selection test for rheumatoid arthritis

Payor Benefits

Reduces patient cycling - Potentially large savings for payors

References:
1. Myasoedova et al. Arthritis & Rheumatology 2010
2. Pitzalis et al. Nature Reviews Rheumatology. 2020.

Thank You